This retrospective study assessed the diagnostic performance of prostate MRI by estimating the proportion of clinically significant #ProstateCancer (csPCa) in patients without prostate pathology. It found varying csPCa proportions based on PI-RADS scores, with sensitivity of 76.6–77.3%, specificity of 67.5–78.6%, and NPV of 84.4–87.2%. (Hirotsugu Nakai et al.)






